Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of zinc finger protein 394 (znf394) in the treatment of cardiac hypertrophy

A zinc finger protein, a technique for cardiac hypertrophy, applied in the drug for relieving and/or treating cardiac hypertrophy, the function and application of zinc finger protein 394 (ZNF394) in the treatment of cardiac hypertrophy, in the field of preparation and prevention, and can solve limited problems, etc. To achieve the effect of anti-cardiac fibrosis myocardial hypertrophy, inhibition of myocardial hypertrophy, and protection of cardiac function

Active Publication Date: 2020-02-14
WUHAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the relevant research on ZNF394 is still very limited,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of zinc finger protein 394 (znf394) in the treatment of cardiac hypertrophy
  • Application of zinc finger protein 394 (znf394) in the treatment of cardiac hypertrophy
  • Application of zinc finger protein 394 (znf394) in the treatment of cardiac hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] [Example 1] Expression of ZNF394 in the hearts of normal people and patients with cardiomyopathy

[0083] SDS-PAGE-Western blot test (Western blot) was performed on proteins extracted from the hearts of normal human hearts (individuals donated by non-cardiac causes of death) and hearts of patients with dilated cardiomyopathy (recipients replaced by patients undergoing heart transplantation, DCM). ), combined with antibodies that specifically recognize ZNF394 protein and cardiomyocyte hypertrophy markers ANP (Millipore, AB2232) and β-MHC (santa cruz, sc53090) to detect the expression of ZNF394 (AVIVA, ARP37322_P050, GAPDH (Cell Signaling Technology , 2128) as an internal reference. The test results are as follows figure 1 As shown, the expression of cardiomyocyte hypertrophy markers ANP and β-MHC in the hearts of patients with dilated cardiomyopathy was significantly up-regulated, and the expression of ZNF394 was significantly down-regulated ( figure 1 );

[0084] [Exa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of zinc finger protein 394 in protecting cardiac function, preventing cardiac fibrosis and / or preventing, relieving and / treating myocardial hypertrophy, and belongs to the field of gene applications. Determined are that in a model with myocardial hypertrophy, expression of the ZNF 394 is significantly reduced when compared to a normal group, that inhibition on ZNF 394 expression significantly promotes myocardial hypertrophy and fibrosis and deteriorates cardiac function, and that promotion on ZNF 394 over-expression significantly inhibits myocardial hypertrophy and fibrosis and protects cardiac function. The ZNF 394 may serve as a pharmaceutical target for screening pharmaceuticals used for protecting cardiac function, preventing cardiac fibrosis and / or preventing, relieving and / treating myocardial hypertrophy; the ZNF 394 may serve as a target gene in gene therapy and serve for the design and preparation of the pharmaceuticals / or biological regents used for protecting cardiac function, preventing cardiac fibrosis and / or preventing, relieving and / treating myocardial hypertrophy, and an effective novel way to treat myocardial hypertrophy is provided.

Description

technical field [0001] The invention belongs to the field of gene function and application, and particularly relates to the function and application of a zinc finger protein 394 (ZNF394) in the treatment of cardiac hypertrophy, specifically the application in the preparation of drugs for preventing, alleviating and / or treating myocardial hypertrophy. Background technique [0002] Hypertrophic cardiomyopathy (HCM) is a compensatory response of the myocardium to long-term biomechanical pressure or increased volume load, which is commonly seen in cardiovascular diseases such as hypertension and aortic stenosis. It is characterized by increased synthesis and increased extracellular matrix [1-3]. Hypertension and senile degenerative aortic valve disease are on the rise year by year in our country. Cardiac hypertrophy and the incidence of hypertension and heart disease caused by hypertension and other diseases also increase thereupon. Although myocardial hypertrophy can initiall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/17C12Q1/6883A61P9/00
Inventor 李红良徐亚伟赵逸凡王丕晓张晓晶
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products